{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:45:57Z","timestamp":1792003557153,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T00:00:00Z","timestamp":1585267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ebiom.2020.102755","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T21:41:44Z","timestamp":1587678104000},"page":"102755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma"],"prefix":"10.1016","volume":"55","author":[{"given":"Xinan","family":"Sheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xieqiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanliang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieming","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ebiom.2020.102755_bib0001","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3322\/caac.21411","article-title":"Treatment of renal cell carcinoma: current status and future directions","volume":"67","author":"Barata","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ebiom.2020.102755_bib0002","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2020.102755_bib0003","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1158\/1078-0432.CCR-07-4921","article-title":"Improved identification of von Hippel\u2013Lindau gene alterations in clear cell renal tumors","volume":"14","author":"Nickerson","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2020.102755_bib0004","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von Hippel\u2013Lindau disease tumor suppressor gene","volume":"260","author":"Latif","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2020.102755_bib0005","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2004.05.061","article-title":"Role of VHL gene mutation in human cancer","volume":"22","author":"Kim","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2020.102755_bib0006","doi-asserted-by":"crossref","first-page":"680s","DOI":"10.1158\/1078-0432.CCR-06-1865","article-title":"The von Hippel\u2013Lindau tumor suppressor protein and clear cell renal carcinoma","volume":"13","author":"Kaelin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2020.102755_bib0007","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/sj.bjc.6605298","article-title":"Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma","volume":"101","author":"Patard","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ebiom.2020.102755_bib0008","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrm.2016.87","article-title":"Mechanisms and regulation of endothelial VEGF receptor signalling","volume":"17","author":"Simons","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ebiom.2020.102755_bib0009","first-page":"1","article-title":"Synchronous inhibition of mTOR and VEGF\/NRP1 axis impedes tumor growth and metastasis in renal cancer","volume":"3","author":"Pal","year":"2019","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.ebiom.2020.102755_bib0010","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fonc.2017.00286","article-title":"Non-canonical mechanisms regulating hypoxia-inducible factor 1 alpha in cancer","volume":"7","author":"Iommarini","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.ebiom.2020.102755_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/897025","article-title":"Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis","volume":"2013","author":"Frost","year":"2013","journal-title":"J Oncol"},{"key":"10.1016\/j.ebiom.2020.102755_bib0012","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.3390\/ijms19082453","article-title":"Role of mTOR signaling in tumor microenvironment: an overview","volume":"19","author":"Conciatori","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ebiom.2020.102755_bib0013","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2020.102755_bib0014","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2020.102755_bib0015","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/annonc\/mdq342","article-title":"Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma","volume":"22","author":"Patil","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ebiom.2020.102755_bib0016","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1093\/annonc\/mdt228","article-title":"A multinational phase II trial of bevacizumab with low-dose interferon-\u03b12a as first-line treatment of metastatic renal cell carcinoma: BEVLiN","volume":"24","author":"Melichar","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ebiom.2020.102755_bib0017","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1200\/JCO.2008.19.3342","article-title":"Randomized phase II trial of firstline treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ebiom.2020.102755_bib0018","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2020.102755_bib0019","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"10189","key":"10.1016\/j.ebiom.2020.102755_bib0020","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"9807","key":"10.1016\/j.ebiom.2020.102755_bib0021","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ebiom.2020.102755_bib0022","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.ebiom.2020.102755_bib0023","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"9637","key":"10.1016\/j.ebiom.2020.102755_bib0024","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"issue":"2 Pt 2","key":"10.1016\/j.ebiom.2020.102755_bib0025","doi-asserted-by":"crossref","first-page":"764s","DOI":"10.1158\/1078-0432.CCR-06-1975","article-title":"Opportunities and obstacles to combination targeted therapy in renal cell cancer","volume":"13","author":"Sosman","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ebiom.2020.102755_bib0026","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/cncr.26429","article-title":"Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma","volume":"118","author":"Molina","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ebiom.2020.102755_bib0027","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3816\/CGC.2009.n.004","article-title":"Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma","volume":"7","author":"Patel","year":"2009","journal-title":"Clin Genitourin Cancer"},{"issue":"Suppl 18","key":"10.1016\/j.ebiom.2020.102755_bib0028","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1200\/jco.2007.25.18_suppl.3512","article-title":"A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies","volume":"25","author":"Patnaik","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ebiom.2020.102755_bib0029","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1002\/cncr.25931","article-title":"A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma","volume":"117","author":"Harzstark","year":"2011","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.ebiom.2020.102755_bib0030","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ebiom.2020.102755_bib0031","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1470-2045(11)70124-3","article-title":"Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial","volume":"12","author":"Negrier","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ebiom.2020.102755_bib0032","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.2013.50.5305","article-title":"Randomized phase III trial of temsirolim us and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial","volume":"32","author":"Rini","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2020.102755_bib0033","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1592\/phco.27.8.1125","article-title":"Sorafenib and sunitinib: novel targeted therapies for renal cell cancer","volume":"27","author":"Grandinetti","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ebiom.2020.102755_bib0034","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003495-200969020-00006","article-title":"Sorafenib: a review of its use in advanced hepatocellular carcinoma","volume":"69","author":"Keating","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.ebiom.2020.102755_bib0035","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1634\/theoncologist.2012-0055","article-title":"Concise drug review: pazopanib and axitinib","volume":"17","author":"van Geel","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.ebiom.2020.102755_bib0036","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2020.102755_bib0037","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1634\/theoncologist.2009-0225","article-title":"Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer","volume":"15","author":"Scagliotti","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.ebiom.2020.102755_bib0038","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11912-011-0154-3","article-title":"Development of second-generation VEGFR tyrosine kinase inhibitors: current status","volume":"13","author":"Bhargava","year":"2011","journal-title":"Curr Oncol Rep"},{"issue":"15_suppl","key":"10.1016\/j.ebiom.2020.102755_bib0039","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1200\/JCO.2017.35.15_suppl.4575","article-title":"A phase I clinical trial of CM082 (X-82) in combination with everolimus for treatment of metastatic renal cell carcinoma","volume":"35","author":"Sheng","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2020.102755_bib0040","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S1470-2045(17)30764-7","article-title":"Anti-VEGFR, PDGFR, and CSF1R tyrosine kinase inhibitor CM082 (X-82) in combination with everolimus for treatment of metastatic renal cell carcinoma: a phase 1 clinical trial","volume":"18","author":"Yan","year":"2017","journal-title":"Lancet Oncol"},{"issue":"15_Suppl","key":"10.1016\/j.ebiom.2020.102755_bib0041","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1200\/jco.2012.30.15_suppl.3041","article-title":"Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumors","volume":"30","author":"Moore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15_Suppl","key":"10.1016\/j.ebiom.2020.102755_bib0042","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1200\/JCO.2018.36.15_suppl.2580","article-title":"Vorolanib (CM082) in Chinese patients with advanced solid tumor: a phase 1, open-label, dose escalation study","volume":"36","author":"Song","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ebiom.2020.102755_bib0043","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00280-018-3599-3","article-title":"Pharmacodynamic study using FLT PET\/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel","volume":"82","author":"Scarpelli","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"10.1016\/j.ebiom.2020.102755_bib0044","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ebiom.2020.102755_bib0045","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2020.102755_bib0046","series-title":"Proceedings of the annual congress of the European Society for medical oncology","article-title":"Efficacy of cabozantinib (C) after PD-1\/PD-L1 checkpoint inhibitors in metastatic renal cell carcinoma (mRCC): the Gustave Roussy experience","author":"Derosa","year":"2017"},{"key":"10.1016\/j.ebiom.2020.102755_bib0047","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1200\/JCO.2018.36.6_suppl.682","article-title":"Outcomes of patients (pts) with metastatic clear-cell renal cell carcinoma (mCCRCC) treated with second-line (2\u00a0L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1\u00a0L) immune checkpoint inhibitors (ICI)","volume":"36","author":"Shah","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2020.102755_bib0048","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1634\/theoncologist.2017-0534","article-title":"Second-line treatment landscape for renal cell carcinoma: a comprehensive review","volume":"23","author":"Tannir","year":"2018","journal-title":"Oncologist"},{"issue":"6_suppl","key":"10.1016\/j.ebiom.2020.102755_bib0049","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1200\/JCO.2020.38.6_suppl.644","article-title":"Efficacy and safety of lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: Russian multicenter observational study ROSLERCM","volume":"38","author":"Volkova","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ebiom.2020.102755_bib0050","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1634\/theoncologist.2018-0740","article-title":"Phase I, first-in-human, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of vorolanib in patients with advanced solid tumors","volume":"24","author":"Bendell","year":"2019","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ebiom.2020.102755_bib0051","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mdv612","article-title":"Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)","volume":"27","author":"Motzer","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ebiom.2020.102755_bib0052","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/annonc\/mdv166","article-title":"Clinical usefulness of PI3K\/Akt\/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines","volume":"26","author":"Bodnar","year":"2015","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ebiom.2020.102755_bib0054","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/iju.13776","article-title":"Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: a phase 1 study","volume":"25","author":"Matsubara","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.ebiom.2020.102755_bib0053","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.18632\/oncotarget.23163","article-title":"Elucidating mechanisms of sunitinib resistance in renal cancer: an integrated pathological-molecular analysis","volume":"9","author":"Butz","year":"2018","journal-title":"Oncotarget"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396420301304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396420301304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T01:03:24Z","timestamp":1715043804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396420301304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":54,"alternative-id":["S2352396420301304"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2020.102755","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2020.102755","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102755"}}